[Tumor-associated antigen CA-125 in patients with ovarian cancer receiving various combinations of therapy].

A dynamic immuno-enzymatic assay of CA 125 was carried out in 43 patients (230 tests) with ovarian tumors receiving chemotherapy alone (group 1), surgery + adjuvant chemotherapy (group 2), or neoadjuvant chemotherapy + surgery + adjuvant chemotherapy (group 3). Mean concentration of CA 125 before treatment was 1,635.0 (362.